FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

$1 vol

Order book

Market Rules

Resolves Yes if the FDA's decision on BBP-418 by Ml Bio Solutions Inc. in 2026 is a full approval or an accelerated approval.Outcome verified from AppliedXL.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

BBP-418 (also known by its chemical name ribitol) is an experimental oral small-molecule drug being developed by BridgeBio to treat a rare inherited muscle disease called limb-girdle muscular dystrophy type 2I (LGMD2I/R9). Think of it like a missing ingredient in a factory: the disease prevents muscle cells from attaching a critical sugar coating to a key protective protein, and BBP-418 supplies the raw material the factory needs to get that process running again. It is taken orally and was shown in the FORTIFY trial to significantly boost levels of the properly-coated protein in patients, which appears to translate into meaningful improvements in muscle and lung function.

Note: this event is mutually exclusive.

Timeline and payout

Market openJun 17, 2026 · 5:30pm EDT

Market closesAfter the outcome occurs

Projected payout30 minutes after closing

This market will close early if the FDA issues a decision on BBP-418 before Jan 1, 2027 Otherwise, it closes by Dec 31, 2026 at 11:59pm EST.

SeriesKXBBP418

EventKXBBP418-27

MarketKXBBP418-27-Y

Insider trading is prohibited

The following are prohibited from trading this contract:

Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.